Kurtin Sandra E
Arizona Cancer Center, Tucson, USA.
Oncology (Williston Park). 2007 Oct;21(11 Suppl Nurse Ed):41-8.
Innovations in the diagnosis, risk stratification, and treatment of the myelodysplastic syndromes (MDS) have provided several new therapeutic options and renewed hope for patients with the disease. Optimal treatment requires careful evaluation of each patient using newly established criteria. Identifying the common symptoms in the MDS patient, integrating new therapies with novel mechanisms of anti-tumor activity and unique toxicity profiles, and developing tools to assist patients receiving these treatments have created unique challenges for the oncology nurse. Many of the emerging therapies have shown promise in tumor response and may be administered over extended periods of time. Most allow patients to be treated in an outpatient setting. This article will explore the diagnosis, treatment planning, and clinical management of patients with MDS.
骨髓增生异常综合征（MDS）在诊断、风险分层和治疗方面的创新为该病患者提供了多种新的治疗选择，并重新点燃了希望。最佳治疗需要使用新制定的标准对每位患者进行仔细评估。识别MDS患者的常见症状、将具有新型抗肿瘤活性机制和独特毒性特征的新疗法相结合，以及开发辅助接受这些治疗的患者的工具，给肿瘤护理人员带来了独特的挑战。许多新兴疗法在肿瘤反应方面已显示出前景，并且可能需要长期给药。大多数疗法允许患者在门诊接受治疗。本文将探讨MDS患者的诊断、治疗规划和临床管理。
